Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study
BE Strober, K Menon, A McMichael… - Archives of …, 2009 - jamanetwork.com
Objective To assess the efficacy of alefacept for the treatment of severe alopecia areata
(AA). Design Multicenter, double-blind, randomized, placebo-controlled clinical trial. Setting
Academic departments of dermatology in the United States. Participants Forty-five
individuals with chronic and severe AA affecting 50% to 95% of the scalp hair and resistant
to previous therapies. Intervention Alefacept, a US Food and Drug Administration–approved
T-cell biologic inhibitor for the treatment of moderate to severe plaque psoriasis. Main …
(AA). Design Multicenter, double-blind, randomized, placebo-controlled clinical trial. Setting
Academic departments of dermatology in the United States. Participants Forty-five
individuals with chronic and severe AA affecting 50% to 95% of the scalp hair and resistant
to previous therapies. Intervention Alefacept, a US Food and Drug Administration–approved
T-cell biologic inhibitor for the treatment of moderate to severe plaque psoriasis. Main …